Deargen Inc., an AI-powered drug discovery and development company, announced on the 24th that it has raised US$17million in a series B financing round. This will be used to accelerate in-house pipeline by establishing a drug development research institute.

The company plans to establish an AI-integrated new drug development system that supports not only the initial stages of a study, such as from target discovery to substance design but also synthesis and drug development.

Sequence Based, Ai-Driven Drug Discovery Company, Deargen Raises Us$17 Million In Seriesb Financing Round To Accelerate In-House Pipeline

Description

Company Information

Funding Insights

Sequence Based, Ai-Driven Drug Discovery Company, Deargen Raises Us$17 Million In Seriesb Financing Round To Accelerate In-House Pipeline

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information